C
Constantine S. Mitsiades
Researcher at Harvard University
Publications - 382
Citations - 35840
Constantine S. Mitsiades is an academic researcher from Harvard University. The author has contributed to research in topics: Bortezomib & Multiple myeloma. The author has an hindex of 87, co-authored 370 publications receiving 33304 citations. Previous affiliations of Constantine S. Mitsiades include Brigham and Women's Hospital & Celgene.
Papers
More filters
Journal ArticleDOI
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore,Ghayas C Issa,Madeleine E. Lemieux,Peter B. Rahl,Junwei Shi,Hannah M. Jacobs,Efstathios Kastritis,Timothy Gilpatrick,Ronald M. Paranal,Jun Qi,Marta Chesi,Anna C. Schinzel,Michael R. McKeown,Timothy P. Heffernan,Christopher R. Vakoc,P. Leif Bergsagel,Irene M. Ghobrial,Paul G. Richardson,Richard A. Young,William C. Hahn,William C. Hahn,Kenneth C. Anderson,Andrew L. Kung,James E. Bradner,Constantine S. Mitsiades +24 more
TL;DR: In this paper, a small-molecule bromodomain inhibitor, JQ1, was used to identify BET proteins as regulatory factors for c-Myc oncoprotein.
Journal ArticleDOI
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu,Richard E. Middleton,Huahang Sun,MarkVic Naniong,Christopher J. Ott,Constantine S. Mitsiades,Kwok-Kin Wong,James E. Bradner,William G. Kaelin,William G. Kaelin +9 more
TL;DR: It is shown that lenalidomide-bound cereblon acquires the ability to target for proteasomal degradation two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3).
Journal ArticleDOI
NF-κB as a Therapeutic Target in Multiple Myeloma *
Teru Hideshima,Dharminder Chauhan,Paul G. Richardson,Constantine S. Mitsiades,Nicholas Mitsiades,Toshiaki Hayashi,Nikhil C. Munshi,Lenny Dang,Alfredo C. Castro,Vito Palombella,Julian Adams,Kenneth C. Anderson +11 more
TL;DR: These studies demonstrate that specific targeting of NF-κB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu.
Journal ArticleDOI
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima,Constantine S. Mitsiades,Giovanni Tonon,Paul G. Richardson,Kenneth C. Anderson +4 more
TL;DR: Recent oncogenomic studies have further advanced the understanding of the molecular pathogenesis of multiple myeloma, providing the framework for new prognostic classification and identifying new therapeutic targets.
Journal ArticleDOI
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Paul G. Richardson,Robert L. Schlossman,Robert L. Schlossman,Edie Weller,Edie Weller,Teru Hideshima,Teru Hideshima,Constantine S. Mitsiades,Constantine S. Mitsiades,Faith E. Davies,Faith E. Davies,Richard Leblanc,Richard Leblanc,Laurence Catley,Laurence Catley,Deborah Doss,Deborah Doss,Kathleen Kelly,Kathleen Kelly,Mary McKenney,Mary McKenney,Julie Mechlowicz,Julie Mechlowicz,Andrea Freeman,Andrea Freeman,Reggie Deocampo,Reggie Deocampo,Rebecca Rich,Rebecca Rich,Joan J. Ryoo,Joan J. Ryoo,Dharminder Chauhan,Dharminder Chauhan,Kathe Balinski,Kathe Balinski,Jerome B. Zeldis,Jerome B. Zeldis,Kenneth C. Anderson,Kenneth C. Anderson +38 more
TL;DR: This study provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease and shows no significant somnolence, constipation, or neuropathy has been seen in any cohort.